SAO PAULO - The governor of Brazil's São Paulo state said on Wednesday that Phase 3 clinical trials of a potential COVID-19 vaccine developed by China's Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December.
Some 9,000 Brazilians are participating in the Sinovac vaccine trials, which are being conducted by the Butantan Institute in Sao Paulo city, the state capital. One such vaccine is being developed by AstraZeneca, which has had to pause global trials after an unexplained illness in a participant in Britain.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: